Latest Eribulin Stories
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits.
Eribulin (trade name: Halaven®) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.
- Partnership Based on Open Innovation That Leverages Eisai's Natural Product Chemistry-Based Drug Discovery Platform -Tokyo, July 17, 2012 - (JCN Newswire) - Eisai Co., Ltd.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.